Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2

Area of Science:

• Molecular Biology
• Biochemistry
• Cancer Research

Background:

• Hypoxia-Inducible Factor (HIF) transcription factors are crucial for cellular oxygen sensing and homeostasis.
• Dysregulated HIF activity is linked to cancer development and metastasis.
• Targeting HIF offers a therapeutic strategy for various cancers.

Purpose of the Study:

• To identify and characterize novel small molecule antagonists of the HIF-2 transcription factor.
• To investigate the binding mechanism and isoform selectivity of these antagonists.
• To explore their potential for therapeutic development in cancer.

Main Methods:

• Identification of small molecules binding to an internal cavity in the HIF-2α subunit's C-terminal PAS domain.
• Characterization of a new class of chiral small molecule ligands.
• Assessment of binding affinity, cellular inhibition, and conformational changes.

Main Results:

• A novel class of chiral small molecule ligands demonstrated the highest affinity binding to HIF-2.
• These compounds provided the most effective and isoform-selective inhibition of HIF-2 in cellular models.
• The ligands induced the largest reported protein conformation changes, elucidating the antagonism mechanism.

Conclusions:

• The identified small molecules represent a promising new class of HIF-2 antagonists.
• These findings deepen the understanding of HIF-2 antagonism molecular mechanisms.
• The results suggest pathways for developing even higher affinity and potency HIF-2 inhibitors for cancer treatment.